Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.188.38.17
dgid:
enl:
npi:0
Growth Hormone Deficiency
Journal Scan

Weekly GHD treatment shows sustained efficacy over 3 years

Posted on

Once-weekly treatment with somapacitan in children with growth hormone deficiency (GHD) showed sustained efficacy over 3 years, according to a study. All assessed height-based outcomes had similar safety and tolerability to daily growth hormone treatment.

-Advertisement-
-Advertisement-

In this multicenter, randomized, controlled, phase 2 study, 59 children with GHD were randomized to receive somapacitan at 0.04, 0.08, or 0.16 mg/kg/week or daily GH at 0.034 mg/kg/day (equivalent to 0.238 mg/kg/week) for the first year. Patients on somapacitan received 0.16 mg/kg/week in the subsequent years.  Overall, 53 children completed the 3-year period.

At year 3 the estimated treatment difference in height velocity was 0.16/0.16 mg/kg/week for somapacitan versus 0.8 cm/year,

From baseline to year 3, change in height standard deviation score was comparable between somapacitan 0.16/0.16 mg/kg/week, the pooled somapacitan groups, and daily GH, with a gradual increase observed for all groups. At the end of the study, height standard deviation score was similar for the pooled somapacitan groups and daily GH group.

Reference
Sävendahl L, Battelino T, Rasmussen MH, et al. Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3. J Clin Endocrinol Metab. 2021;dgab928. doi: 10.1210/clinem/dgab928. Epub ahead of print. PMID: 34964458.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-